Purpose: Review articles are an important source of summary information for practising clinicians to assist them in remaining current with the rapidly expanding medical literature. Consequently it is essential that these be of the highest quality. In this study we evaluate, according to published criteria, the methodological quality of review articles (R) including metaanalyses (MA) appearing in a major cancer journal, Journal of Clinical Oncology (JCO), 1983-1995. Methods: A hand-search of JCO was performed, from the first issue January 1983 through December 1995, to identify R, defined as publications that describe and comment on studies relevant to a specific topic or clinical intervention. Only those dealing with aspects of treatment of human cancer were considered further. Methodological quality was first assessed using 8 criteria proposed by Mulrow [1], rated independently by two medical oncologists as: specified, unclear or not specified. MA, including studies of dose intensity, were further analyzed according to 23 more detailed criteria proposed by Sacks et al. [2] and rated as adequate, partial or no/unknown compliance.
Introduction
The Cochrane Collaboration is an international network of individuals helping to prepare, maintain, and disseminate systematic reviews (Cochrane Reviews) of the effects of health care. Building on the experience of the first collaborative review group (Cochrane Pregnancy and Childbirth Group), the Collaboration has rapidly expanded into other areas of health care such as stroke, schizophrenia, sub-fertility and musculo-skeletal diseases. In order to promote, coordinate, facilitate and support reviews in the cancer field, the Cochrane Cancer Network has recently been established.
A number of articles have discussed the quality of reviews published in scientific journals [1] [2] [3] [4] [5] [6] though none have focused on the cancer field. As part of the ground-work to establish the Cancer Network, we felt it would be useful to assess reviews in a major oncology journal.
JCO was launched in January 1983. Its stated aim [7] was "to be a focus for communication for research pertaining to the clinical disciplines of oncology". In that first editorial, J. Bertino (Editor-in-Chief) wrote "although the primary purpose of this journal is to publish research papers of interest to oncologists, other features such as reviews, points of view, letters to the editor, and editorials will serve to broaden the scope of the journal". After one year, the journal had published 69 original articles and 11 reviews or 'points of view' articles [8] . In December 1987, evaluating the first 5 years of publication, Bertino [9] commented that "both solicited and unsolicited reviews and points of view have served an important educational function for our readers".
It is generally agreed that high quality reviews are a critical resource for practising clinicians in keeping up-to-date with the rapidly expanding medical literature. In July 1994, the current Editor-in-Chief of JCO, G. Canellos, stated "we have prioritized the publication of timely reviews by experts on significant topics of importance to our readership" [10] . However, unless reviews are conducted according to high scientific standards their conclusions may be seriously flawed [1, 2, 11] . JCO has recognized the need for methodological guidelines for reporting cancer clinical trials [12] , and from November 1985, 'Information for Contributors' in each issue of JCO refers authors reporting clinical trials to articles by Simon and Wittes [13] 'Methodological guidelines for reports of clinical trials' and Zelen [14] 'Guidelines for published papers on cancer clinical trials: Responsibilities of editors and authors'. Currently (December 1995), guidance to authors of editorials and reviews is limited to a paragraph stating "Editorials and review articles may be solicited by the Editor. Unsolicited review articles will also be considered. These manuscripts must be prepared in a manner appropriate for other papers and will be reviewed as are original articles submitted for consideration." An editorial did appear in the June 1992 issue of JCO [15] entitled 'Meta-analyses need new publication standards'. This emphasized a minimum need for a research plan, a description of the literature search, an evaluation of population heterogeneity and a presentation of studyspecific data. Arguably, these criteria could be applied to all reviews.
In 1987, C. Mulrow [1] published a study of the methodological quality of recent review articles. Fifty reviews published during June 1985-June 1986 in four major medical journals (Annals of Internal Medicine, Archives of Internal Medicine, The Journal of the American Medical Association, New England Journal of Medicine) were evaluated according to eight explicit criteria (purpose, data identification, data selection, validity assessment, qualitative synthesis, quantitative synthesis, summary, future directives) adapted from published guidelines for information synthesis. Of the 50 articles, 17 (34%) satisfied three of eight criteria; 32 (64%) satisfied four or five criteria; and one satisfied six criteria. None met all her criteria and she concluded that "current medical reviews do not routinely use scientific methods to identify, assess, and synthesize information". Also in 1987, Sacks et al. [2] did a similar analysis of those quantitative reviews of research studies that are termed meta-analyses. They evaluated the quality of 86 meta-analyses of reports of randomized controlled trials in the English language literature using a scoring method that considered 23 items in six major areas -study design, combinability, control of bias, statistical analysis, sensitivity analysis and application of results. Only 24 (28%) meta-analyses addressed all six areas, with 31 (36%), 25 (29%), 5 (6%) and 1 (1%) addressing five, four, three and two areas respectively. Of the 23 individual items, between one and 14 were dealt with adequately (mean ± SD, 7.7 ± 2.7).
The purpose of the present study is to assess the quality, using a systematic approach based on published criteria [1, 2] , of review articles pertaining to cancer treatment appearing in JCO since the first issue in 1983 to the current time (December 1995) -a 13-year time span. As meta-analysis and dose intensity studies can be regarded as quantitative reviews, these were included. We elected to use Mulrow's criteria, as they were similar to those proposed by others [3, 6] , and they enable comparison of the findings in a major American oncology journal with those for four major American general medicine journals both at a similar period in time, and over a later time period. These criteria can also be used to assess whether there have been changes in the quality of reviews in JCO over time.
Meta-analyses appeared for the first time in JCO in 1991. As most meta-analyses in our sample were found to have the highest ratings according to Mulrow's criteria, a subsequent secondary objective was to evaluate all the meta-analyses according to the 23 detailed criteria described by Sacks et al. Dose intensity studies are similar to meta-analyses in some respects and thus those published in JCO over the same period also are included for evaluation.
Methods
JCO was hand-searched by one investigator (VB) from the first issue January 1983 through to December 1995 (156 issues) to identify (a) review articles, (b) randomized controlled trials (RCTs). Hand searching has been shown to be the most efficient method of identifying RCTs [16, 17] . This journal was chosen because it has an established policy of publishing regular review articles. It also achieved the highest score for numbers of RCTs published in breast cancer, based on an optimal Medline search strategy [17] for the years 1985, 1990, 1994 . In a similar search for the years 1980,1986,1992 for RCTs in sarcoma, JCO ranked third. Articles describing RCTs will be entered into an International Register of Randomized Controlled Trials of Health Care, a joint project of the Cochrane Collaboration and the National Library of Medicine [17] , and will not be considered further here.
Review articles were denned as publications that describe and comment on studies relevant to a specific topic or clinical intervention. Original data from the author(s) are not usually presented in such papers, although their own published work is often quoted. Most of the articles (88%) in our sample were labelled 'Review Article' by the Journal editors but some had other headings such as 'Karnofsky Memorial Lecture', 'Rapid Publication', 'Special Article', and uncategorized articles also fitted the definition. Articles using quantitative methodology, usually described as meta-analyses or overviews, were included, as were retrospective analyses of the influence of chemotherapy dose intensity on survival or other outcomes of cancer treatment. Clinical case reports, with review of the literature, were excluded because of their limited scope.
Articles were selected for inclusion in the study if there was agreement between the two authors (both medical oncologists -VB, CW) that they dealt with aspects of treatment of any form of human cancer (including complications of therapy and supportive care). The methodological quality of these reviews was assessed independently by VB and CW using eight explicit criteria, proposed by Mulrow [1] (Table 3) .
Each criterion was categorized as specified, unclear or not specified. The category 'unclear' was used when the reviewers) had made an incomplete attempt to address the point, or in situations where some information was presented but in an ambiguous or unfocused way. The final score was determined by consensus between VB and CW but the extent of disagreement is reported. As both investigators already had some familjarity with sections of the subject matter blinding of the assessors to authorship or institutional affiliation was not feasible.
As Mulrow's criteria did not provide good discrimination between articles that were described as meta-analyses, or quantitative overviews, including studies of dose intensity, these were further analysed according to the 23 more detailed criteria proposed by Sacks et al. [2] and compliance was scored adequate, partial or none/unknown.
Results

Review articles
Scope of analysis (inclusion/exclusion)
One hundred and twenty-two articles (References 8-139 shown in Appendix 1) were included and fifty four were excluded ( 
Review topics
The topics of reviews can be divided into nine main categories, and their distribution by year is shown in Table 2 .
Quality assessment according to Mulrow's criteria
Preliminary examination of the 122 reviews to be analyzed showed that 16 [30, 45, 51, 78, 79, 84, 89, 93, 99, 100, 108, 111, 112, 115, 128, 131] used meta-analytic or quantitative methods. Six of these were dose intensity studies. These were separated out for reporting purposes (Table 3) , and they were further analyzed using the criteria of Sacks et al. [2] , shown in Table 5 .
Thus Inter-observer agreement in scoring the eight criteria of Mulrow was high. Of 976 items (122 reviews x 8) there was complete agreement in 916 (93.9%). There were 51 items for which disagreement was minor (specified vs. unclear; not specified vs. unclear) and nine (< 1%) for which there was major disagreement (specified vs. not specified). All disagreements were resolved by re-reading and discussing the relevant papers.
Qualitative reviews (QR)
Purpose. In contrast with Mulrow, we generally found that the purpose was clearly stated (99% vs. 80% for Mulrow) in the title or opening paragraph. The structured abstract form used in JCO from 1992 onwards appears to have enhanced the clarity of statements of purpose. The scope and focus of QR varied enormously from the highly specific, e.g., neurologic toxicity of cytarabine therapy [81] , to broad ranging, e.g., natural history and treatment of gastrointestinal neuro-endocrine tumors [54] . The purpose of the latter article (a Karnofsky Memorial Lecture) was scored as 'unclear' because the title 'An odyssey in the land of small tumors' was ambiguous (but eye-catching!) and the scope of the review was not immediately apparent.
Data identification. Adequate techniques for identifying published articles for review, including at a minimum a computer-assisted search of an English-language database such as Medline over a relevant time period, were evident in 11.3% of reviews, only slightly higher than the 2% reported by Mulrow.
Data selection. Inclusion/exclusion of studies according to predetermined explicit criteria reduces bias in the selection process. Predetermined criteria were stated for 10.4% of the QR analysed in our study, compared with 2% in that of Mulrow. Selection undoubtedly occurred, as some authors indicated: e.g., 'selected literature review' [52]; "of approximately 1,000 publications identified for analysis, 233 were selected as representative of important advances in CLL" [123] , yet even in these reviews no criteria were actually specified.
Validity assessment. Mulrow described this as "a standardized methodological assessment of the data". She found this item to be poorly covered (2%), and we found only nine (8.4%) authors made any assessment of the methodological quality of a significant proportion of the individual studies included in their reviews. Qualitative synthesis. We felt that all authors (100%) had made an attempt to integrate the data, pointing out limitations and inconsistencies. Mulrow noted that 16% of the reviews she analyzed only listed findings, with no integration. The vast differences in subject and scope of these 104 QR made it difficult to further categorize the integrative efforts of the reviewer(s).
Summary.
A high proportion of authors (95%) provided a summary of their findings. All articles appearing from 1989 onwards were preceded by an abstract, which was present in 86/104 (83%) of QR. A section entitled Summary/Conclusions appeared at the end of a further 13 (12.5%) QR. Structured abstracts (present from 1992 onwards) improved the clarity of summaries. An adequate summary was present in 74% of reviews surveyed by Mulrow. Future directions. This issue was addressed in 76% of QR sample, a proportion that was substantially higher than that found by Mulrow (42%).
It should be noted that there are limitations to strict application of criteria for data selection and some aspects of validity assessment in reviews of new cytotoxic or biologic agents where the clinical data are limited to phase I/II studies. This was judged to be the case in 15 QR. In such studies quantitative summation also would not be feasible or relevant. Reviews of treatment of rare tumors may surfer from similar limitations.
For comparison with Mulrow's results, we divided our QR into two cohorts spanning the time periods 1983-1989 and 1990-1995, which were approximately equal in size (52 and 54 reviews). The first cohort corresponded more closely in time-frame to the Mulrow study (1985) (1986) ) and contained a similar number of reviews. Table 4A shows that in our first cohort (1983) (1984) (1985) (1986) (1987) (1988) (1989) as in the Mulrow study very few scored 6 or above (4% vs. 2%), and similar numbers scored 4 and 5 (52% vs. 64%) or 3 (42% vs. 34%). In the second JCO cohort (1990-1995) there were 7 (13%) reviews scoring 6 or above, and 41 (76%) scored 4,5 demonstrating an improvement over time (JCO improvement with time 1983-1989 vs. 1990-1995, scores 6 and more P = 0.08, one tailed Fisher's exact test: scores 4 and above P -0.0002, one sided Fisher's exact test).
Similarly, when the scores for the individual criteria in the two JCO cohorts are compared (Table 4B) there is an impression of improvement in the later cohort.
Quantitative reviews (meta-analyses/dose intensity studies)
These quantitative reviews generally scored better in those areas that were weak in the other reviews. Thus, data identification methods were reported in 69% of meta-analysis/dose intensity studies (MA/DI) compared with 12% QR; data selection criteria in 81% of MA/DI compared with 11% of QR; and validity assessment was performed in 56% of MA/DI compared with 9% of QR. Statements of purpose, qualitative review, summaries and future direction were provided with similar frequency.
Quality assessment according to Sacks' criteria
We found that interobserver agreement in scoring the 23 criteria of Sacks et al., although not quite as good as for the Mulrow criteria, was still high. Of 368 items (16 MA/DI x 23) there was complete agreement for 314 (85%). There were 29 items for which disagreement was minor and 25 (7%) instances of major disagreement.
The Abbreviations: A -adequate; P -partial; N -none/unknown. our analysis and the corresponding percentages for 86 studies in the analysis of Sacks et al.
Prospective study design Protocol. In only three (30%) of the MA and none of the DI was a protocol or research plan specifically mentioned. However, the detailed methodology outlined in many of the papers suggested the likelihood of a protocol.
Literature search. In nine (90%) of the MA and three (50%) of the DI, details of the methodology of the literature search were provided.
List of trials analyzed. All MA and DI provided a list or table of included trials, appropriately referenced.
Ranges of patients.
Five (50%) of the MA and two (33%) of the DI provided comprehensive information about relevant patient characteristics (e.g., age, sex, race/ethnic origin, socio-economic status). Partial information was supplied in a further five studies.
Ranges of treatment.
Details concerning types, doses and schedules of treatment were supplied in all MA and DI.
Ranges of diagnosis.
Similarly, compliance was high on this criterion, with insufficient information given only in one study.
Combinability
Criteria. All reviewers provided valid criteria of comparability to justify combining the studies.
Log of rejected trials. Eight (80%) of the MA, but only one of the DI provided information, including references, on trials excluded and the reasons for exclusion.
Measurement. In eight (80%) of MA and two (33%) of DI issues of heterogeneity were assessed and relevant statistical tests applied.
Treatment assignment. All the MA used data from RCTs only, but the six DI included RCTs and non-RCTs and only three of these analyzed the data separately.
Control of bias Selection bias.
We could not find evidence in any of the studies that attempts had been made to avoid bias by deciding to select or reject a paper on its methods, not on its results. Interestingly, Sacks only described one study (1.2%) showing partial compliance with this criterion.
Data extraction bias.
In one study data was extracted by two investigators independently [99] . We also assumed that individual patient data MA, in which data extraction was based on a pre-set protocol and hard endpoints (e.g., survival), would be subject to minimal bias. Thus, there was compliance in four (25%) of our studies.
Inter-observer agreement. The study mentioned above [99] , which used two independent observers to extract data did not, however, provide information concerning the correlation of observations. Because discrepancies in data are usually checked with the relevant trialists providing the data [140] , we assumed this criterion to be fulfilled in individual patient data MA. Thus, only three MA (19%) complied with this criterion.
Source of support. Details of institutional affiliation were provided in 12 instances, and scored as partial compliance. Four groups of reviewers acknowledged financial support, but it was not possible to determine whether there were other sources of support for the remaining reviews. Sensitivity analysis Quality assessment. We found that the scientific quality of included trials, based on assessment of factors such as the randomization process, measurement of patient com- pliance, statistical analysis and handling of withdrawals, was evaluated adequately in three DI and four MA (overall compliance 44%). Detailed checking of these issues is possible in MA using individual patient data.
Statistical analysis
Varying methods. In four MA and two DI studies (total 38%) an attempt was made to examine the data using different assumptions, tests and criteria.
Publication bias. Only two groups of reviewers used statistical methods to explore the effects on the data of adding information from hypothetical negative unpublished studies. In a further three studies the possibility of unpublished data was considered but not thought likely, and these were scored as partial compliance.
Application of results
Caveats. All authors attempted to put the results in the perspective of current practice and made appropriately qualified recommendations, although the attempt was limited in two studies, and also was scored as partial compliance.
Economic impact. Only one MA provided a brief comment on the economic implications of the findings.
Review of the final two columns of Table 5 shows that with the exception of the criterion of source of support, we consistently scored the 16 MA and DI in our analysis higher than Sacks et al. scored their 86 MA. The discrepancy was particularly marked (> 2:1) in certain subsets of the broad categories: prospective design (literature search, log of rejected trials, ranges of treatment and diagnosis); combinability (criteria, measurement); control of bias (data extraction bias); sensitivity analysis (quality assessment, varying methods, publication bias) and application of results (economic impact). Table 6 displays the frequency of 'adequate' ratings of quality in the 16 studies. The range 7-18 is much narrower than for the Sacks study [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] and the mean value ± SD (12.2 ± 3.3 vs. 7.7 ± 2.7) is higher. Five of 16 (31%) scored above 14 which was the highest score (occurring in 2/86 cases) reported by Sacks et al. Table 6 also demonstrates that the scores were highest for individual patient data MA, intermediate for the remaining MA and lowest for the DI.
Number of authors
The number of authors for the 106 QR ranged from 1-6, median two, with two articles published on behalf of a group [83, 127] rather than individual authors. The number of authors was spread evenly between one (26 QR), two (31 QR), three (20 QR), and four/five/six (27 QR).
For the 16 MA/DI, the number of authors ranged from 2-13, median three, with three articles published on behalf of a group [89, 100, 116]. There were two authors for six studies, three authors for four studies and five, seven and 13 authors respectively for the remaining three studies.
There was no relationship between quality score and number of authors. Of the 106 QR, the majority (95 QR) were written by US authors, with five from Canada, five from Europe and one from India. In contrast, only one of the MA/DI had US authorship, whereas seven were from Canada and three from Europe (one with a Japanese co-author). Three MA/DI were published under group authorship, and two with multiple authorship included US investigators.
Discussion
Although the majority of reviews included in this study had been labelled as such by JCO editors, a minority (15%) were not so categorized. Hand-search enabled identification and inclusion of 18 such articles, of which eight were QR, eight were MA and two DI. The benefits of hand-searching in identifying RCTs not retrieved by electronic search strategies [16, 17] is well established.
JCO is the official journal of the American Society of Clinical Oncology, which has a membership strongly biased towards medical oncology. An appropriately similar bias is seen in the subject matter of these 122 reviews of treatment, with 27% focused on a specific drug, drug class or biological agent. In addition, seven out of 10 MA, and all six DI studies evaluated chemotherapy treatments. The majority of reviews (14 of 19) covering specialized techniques or treatment focused on systemic treatment, although in two instances this was combined with radiotherapy.
Several authors [6, 11, 141, 142] have suggested guidelines to assist in critical appraisal of literature reviews. However, we felt that the criteria proposed by Mulrow incorporated most of these, were easy to understand and score, and had the additional advantage that they had already been applied to a cohort of general medical reviews. The excellent inter-observer agreement (94%), with less than 1% major differences, confirmed that the scoring system could be applied by other observers to different subject matter.
Most of the reviews stated a purpose, analyzed data qualitatively, presented a summary and future directions. Except in MA and some DI, authors rarely gave information on literature searches, criteria for selection of included studies and assessment of quality (validity). Quantitative summation was almost entirely confined to MA and DI.
In view of the obvious heterogeneity of the data, we analyzed separately all those studies (MA and DI) which used sophisticated quantitative methodology to integrate the results. To facilitate a comparison with Mulrow's data, we further divided the remaining 106 QR into two approximately equal cohorts, early (1983) (1984) (1985) (1986) (1987) (1988) (1989) ) and late (1990) (1991) (1992) (1993) (1994) (1995) In Mulrow's study and our early cohort, most (94% for both) reviews scored three, four or five out of eight. Mulrow did not report separately scores of four and five. However, the proportion of reviews (Table 4B ) meeting each individual criterion was consistently slightly higher for our early cohort, particularly for purpose (98% vs. 80%), qualitative synthesis (100% vs. 86%), summary (92% vs. 74%) and future directions (67% vs. 42%). Parenthetically, the criterion 'future directives' may be irrelevant with respect to many studies and these scores should be treated with caution when judging overall quality of a review.
In the later cohort, the results were somewhat better, with three reviews achieving a score of six, and four a score of seven. The improvements particularly seemed to be in the areas of data identification, data selection and validity assessment. Although the reviews of cancer treatment seemed to meet the criteria with greater frequency and though there has been some improvement over time, there is no reason for complacency as the key issues of avoiding bias of data identification, data selection and validity assessment were addressed in less than 10% of our later cohort of QR.
JCO is acknowledged as a premier journal in the cancer field, and provides methodological and statistical guidelines for contributors [12] [13] [14] , as well as a rigorous peer review process. Thus it is likely that the problems identified here will be evident, and indeed may be worse, in review articles in other cancer journals.
Meta-analysis is a process of statistically combining the results of previous clinical trials to draw conclusions about therapeutic effectiveness and/or to plan future studies. The methodological pitfalls associated with these types of analyses have been extensively reviewed [4, 5, [143] [144] [145] [146] [147] and an editorial in JCO [15] discussed the need for new publication standards for meta-analysis. Many of these articles have provided criteria for assessing the quality of meta-analyses. We chose to apply those described by Sacks et al., which encompassed most of those suggested by others, and which have been validated on a cohort of published meta-analyses. Inter-observer agreement in scoring Sacks criteria for our 16 MA/DI (85%) was a little lower than that observed for the Mulrow criteria (94%), but was still judged to be satisfactory, particularly as major disagreement was rare (Sacks -7%, Mulrow < 1%).
Our studies scored more highly than the MA reviewed by Sacks et al. In particular, there was more likely to be an adequate literature search, a log of rejected trials and detailed information concerning the ranges of diagnoses and treatments included in individual trials. Issues such as combinability of studies, control of bias and sensitivity analyses were better addressed but the scores were still low. In general, statistical analyses were appropriate except for the consideration of specific statistical errors. It is possible that we were more literal in our interpretation of this particular criterion than Sacks et al. It is difficult to be sure whether there were more sources of financial support than were disclosed and more explicit reporting would be helpful. Formal economic analyses would require considerable resources, but more authors could have considered economic implications.
There are several possible reasons why our MA/DI scored significantly higher than those reviewed by Sacks et al. These include the different time frames of the two studies for Sacks compared with 1984-1995 with 80% published in or after 1991, for the current study) or more consistent standards applied to articles published in one journal versus many. Another possibility is that there are higher standards in MA of cancer clinical trials, or higher publication standards for those published in JCO. It is also possible that the differences are artefactual. We may have interpreted the criteria differently than Sacks. The numbers in our study (sixteen) are small compared with those of Sacks et al., and might give rise to a type 1 error (false positive).
Chalmers et al. [5] also found it difficult to identify causes of variability. In an interesting study, in which 46 of 91 known MA papers were divided into 20 cohorts of studies of similar therapies, ten cohorts contained MA with different statistical conclusions and 14 contained different clinical conclusions. Chalmers found that possible causes of variability such as the different trials included, different policies regarding inclusion of non-randomized and unpublished trials, and different statistical methodologies were not obviously responsible for the differing conclusions.
There was no relationship between quality score and number of authors. The findings with regard to country of origin show that 89% of QR had solely US authorship whereas this was only true for 6% of the MA/DI.
The first DI was published by Canadian authors, and this methodology has been pursued by Canadian investigators, who published four of five of the subsequent studies. Although our numbers are small, it is intriguing to observe that most of the MA have been performed by Canadian and European investigators. 
Conclusions
With the exception of MA/DI, the majority of reviews in JCO did not use systematic methods to identify, assess and synthesize information. Although there was some improvement in the later cohort (1990) (1991) (1992) (1993) (1994) (1995) , there were serious gaps in the areas of data identification, data selection and validity assessment. Even though quantitative methods of integration of data might not always have been appropriate, they could probably have been used more frequently. MA/DI from JCO did score more highly on both sets of criteria, but these results should be viewed with caution because of the small sample size.
Individual patient data meta-analyses, although more labour intensive and costly, do provide the opportunity to adequately address most methodological issues. The use of methods to avoid selection bias, and calculations to test the strength of the evidence in the face of unpublished data, would have enhanced some studies. Consideration of the economic implications of positive findings would provide important contextual information.
In the light of these findings, the value of an initiative such as the Cochrane Collaboration, dedicated to improving the scientific rigour of clinical reviews, is obvious.
International Collaborative Review Groups prepare Cochrane Reviews using a standard organizational and analytical framework supported by a software package, Review Manager. These are assembled into disease related modules which are finally incorporated into the parent database of Cochrane Reviews. Dissemination takes place through a regularly updated CD ROM journal called 'The Cochrane Library' which is available on the Internet. Some groups may also publish their reviews in paper-based journals.
Assembly of the data in electronic format facilitates the maintenance of reviews, with revision of analyses based on feedback and information from new relevant trials. The recently established Cancer Network will coordinate, facilitate and support the establishment and activities of collaborative review groups for various types of cancer, and cancer associated problems.
Although the Cochrane Cancer Network can support and educate clinicians who wish to perform systematic reviews, the majority of literature reviews will still be performed by individuals outside this network. The standard of these reviews would be improved if authors, editors and readers systematically applied any of the sets of criteria now available in the literature. 
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